Skip to main content

Advertisement

Figure 3 | BMC Cancer

Figure 3

From: Epstein-Barr virus infection and clinical outcome in breast cancer patients correlate with immune cell TNF-α/IFN-γ response

Figure 3

Effect of EBV-T and EBV-P on the increase in patient survival as a function of time for different relapses. At 60 months post-diagnosis, the increase in survival is 32% and 8%, respectively, without and with relapse for “EBV-T” patients, versus 12% and 6%, respectively without and with relapse for “EBV-P” patients. Relapse 0 means “no relapse”; relapse 1 means “relapse diagnosed”. EBV-T + and EBV-P + represent patients with detectable EBV DNA in tumor tissue and PBMCs, respectively.

Back to article page